Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 1/2 11Phase 3 7Phase 1 7Phase 4 2Phase EARLY_PHASE1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Dexamethasone 13Bevacizumab 9Saline Solution 8Bupivacaine 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Lenalidomide 7Fluorouracil 7pembrolizumab 6Rituximab 6Prednisone 6Letrozole 6Cisplatin 6Carboplatin 6Sodium Chloride 5Ropivacaine 5Propofol 5Human Papillomavirus Recombinant Vaccine nonavalent 5trametinib 4lenvatinib 4dabrafenib 4cabozantinib 4anlotinib 4Trastuzumab 4Tamoxifen 4Standard of Care 4Paclitaxel 4Immune Checkpoint Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × enfortumab vedotin × 1 year × Clear all
NCT06862219 2026-05-28

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Astellas Pharma Inc

Phase 4 Recruiting
100 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

Phase 4 Recruiting
75 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡